Back to discover
Disease

Hyperphagia

Late-stage therapeutic developmentEmerging research
MeSHHyperphagia
1
Publications
10
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones4View
Results expected 1
Recently completed 1
Other updates 2
Activity timeline4

Clinical trials

8 sponsors · 0 new · 0 completed in the last 12 months (net -2)

The current development programme across all trial phases.

Clinical programme
10
All trials
2
Active
5
Late-stage
3
Completed
Late-stage studies

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Phase 3 · Active, not recruiting · ACADIA Pharmaceuticals Inc.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperphagia in Patients With Prader-Willi Syndrome

Phase 3 · Terminated · Aardvark Therapeutics, Inc.

A Phase 3, Multicenter, Open-Label Extension Study to Assess the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome

Phase 3 · Terminated · Aardvark Therapeutics, Inc.

Effect of Somatostatin on Ghrelin Concentrations, Food Seeking Behaviour and Weight in Patients With Prader-Willi Syndrome

Phase 3 · Terminated · University of British Columbia

A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analogue, on Food-related Behaviors in Patients With Prader-Willi Syndrome

Phase 2/3 · Terminated · Millendo Therapeutics SAS

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Bardet-Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction.

Diabetes, obesity & metabolism · 2024 · 27 cites
Recent publications

Bardet-Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction.

Diabetes, obesity & metabolism · 2024 · 27 cites
Major themes2
  • Bardet-Biedl Syndrome1
  • Diabetes Mellitus, Type 21
Leading journals1
  • Diabetes, obesity & metabolism1
Leading researchers1
  • Tomlinson JW1
Affiliations (unnormalised)1
  • Oxford Centre for Diabetes1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Ingestion of a greater than optimal quantity of food.

Identifiers
MeSHHyperphagia
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.